These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23252359)

  • 21. Payer perspectives on pharmacogenomics testing and drug development.
    Epstein RS; Frueh FW; Geren D; Hummer D; McKibbin S; O'Connor S; Randhawa G; Zelman B
    Pharmacogenomics; 2009 Jan; 10(1):149-51. PubMed ID: 19102724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in PEGylation of important biotech molecules: delivery aspects.
    Ryan SM; Mantovani G; Wang X; Haddleton DM; Brayden DJ
    Expert Opin Drug Deliv; 2008 Apr; 5(4):371-83. PubMed ID: 18426380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The lag from FDA approval to published cost-utility evidence.
    Chambers JD; Thorat T; Pyo J; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory and Economic Considerations of Retinal Drugs.
    Shah AR; Williams GA
    Dev Ophthalmol; 2016; 55():376-80. PubMed ID: 26502165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PEG-modified biopharmaceuticals.
    Bailon P; Won CY
    Expert Opin Drug Deliv; 2009 Jan; 6(1):1-16. PubMed ID: 19236204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical Products.
    Irizarry Rovira AR; Bennet BM; Bolon B; Braendli-Baiocco A; Chandra S; Fleurance R; Garman R; Hutto D; Lane J; Romeike A; Sargeant A; Zimmerman B
    Toxicol Pathol; 2018 Aug; 46(6):616-635. PubMed ID: 30092727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the future of PEGylated therapies?
    Swierczewska M; Lee KC; Lee S
    Expert Opin Emerg Drugs; 2015; 20(4):531-6. PubMed ID: 26583759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):611. PubMed ID: 23981251
    [No Abstract]   [Full Text] [Related]  

  • 29. The economic aspects of drug delivery in asthma.
    Massie RJ; Mellis CM
    Pharmacoeconomics; 1997 May; 11(5):398-407. PubMed ID: 10168029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status and prospects of polyethyleneglycol-modified medicines.
    Ishihara H
    Biol Pharm Bull; 2013; 36(6):883-8. PubMed ID: 23727910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging PEGylated non-biologic drugs.
    Park EJ; Choi J; Lee KC; Na DH
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):107-119. PubMed ID: 30957581
    [No Abstract]   [Full Text] [Related]  

  • 32. How cost-effective are new cancer drugs in the U.S.?
    Lichtenberg FR
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):39-55. PubMed ID: 31906739
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantitative benefit-risk analysis for evaluating drug therapies.
    Kodell RL; Chen JJ
    J Biopharm Stat; 2013; 23(1):231-8. PubMed ID: 23331233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PEGylated drug delivery systems in the pharmaceutical field: past, present and future perspective.
    Sanchez Armengol E; Unterweger A; Laffleur F
    Drug Dev Ind Pharm; 2022 Apr; 48(4):129-139. PubMed ID: 35822253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of US FDA-Approved Drugs Containing Sulfur Atoms.
    Scott KA; Njardarson JT
    Top Curr Chem (Cham); 2018 Jan; 376(1):5. PubMed ID: 29356979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies.
    Gallagher GW; Nowacek D; Gutgsell O; Callaghan BC
    Muscle Nerve; 2021 Dec; 64(6):641-650. PubMed ID: 34448221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New horizons in pharmaceutical technology.
    Kirking DM
    Ann Am Acad Pol Soc Sci; 1983 Jul; (468):182-95. PubMed ID: 10310115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies.
    Buessing M; O'Connell T; Johnson S; Pitluck S; Ciulla TA
    Value Health; 2019 Aug; 22(8):970-971. PubMed ID: 31426938
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications.
    Cioni P; Gabellieri E; Campanini B; Bettati S; Raboni S
    Curr Med Chem; 2022; 29(3):411-452. PubMed ID: 34259137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying mechanism-of-action targets for drugs and probes.
    Gregori-Puigjané E; Setola V; Hert J; Crews BA; Irwin JJ; Lounkine E; Marnett L; Roth BL; Shoichet BK
    Proc Natl Acad Sci U S A; 2012 Jul; 109(28):11178-83. PubMed ID: 22711801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.